# Peri-Operative Antimicrobial Prophylaxis Modulates CD4+ Lymphocyte Immunophenotype Ex Vivo in High-Risk Patients Undergoing Major Elective Surgery—A Preliminary Observational Study

**Authors:** Susi Paketci, Jack Williams, Walter Pisciotta, Richard Loye, Alessia V. Waller, Rahila Haque, David Brealey, Mervyn Singer, John Whittle, Ramani Moonesinghe, Nishkantha Arulkumaran, Timothy Arthur Chandos Snow

PMC · DOI: 10.3390/antibiotics14101026 · Antibiotics · 2025-10-14

## TL;DR

This study shows that antibiotics used before and after surgery can change immune cell behavior, especially in CD4+ lymphocytes, which may affect recovery and infection risk.

## Contribution

The study reveals that cefuroxime specifically alters CD4+ lymphocyte immunophenotype ex vivo in high-risk surgical patients.

## Key findings

- Cefuroxime increased IFN-γ and IL-2 in CD4+ lymphocytes at low and high doses.
- Cefuroxime reduced Th2, Th17, and regulatory markers in CD4+ lymphocytes.
- Higher cefuroxime doses altered Th1 cell viability and surface marker expression.

## Abstract

Background: Post-operative infections are a significant cause of morbidity in patients undergoing major elective surgery. Peri-operative antibiotics are used to reduce the risk of infection. Several antibiotics modulate the host immune response. Objectives: Our objective was to determine the ex vivo immunomodulatory properties of commonly used antibiotics (amoxicillin, cefuroxime, metronidazole, or combined cefuroxime–metronidazole) on monocyte and lymphocyte phenotypes in patients undergoing major elective surgery. Methods: We performed a prospective cohort study of patients aged ≥18 years admitted to the post-anaesthetic care unit following major elective non-cardiac surgery. Peripheral blood mononuclear cells isolated immediately after surgery were incubated with antibiotics with or without a monocyte (heat-killed E. coli) or lymphocyte (CD3/CD28 beads) stimulus ex vivo. Immune cell phenotype was characterised using flow cytometry. Results: Twenty-eight patients were included. All antibiotics tested were associated with a reduction in T-cell viability, and changes to monocytes were minimal. Among CD4+ and CD8+ lymphocytes, cefuroxime increased IFN-γ (at low and high doses) and increased CD4+ lymphocyte IL-2 and IL-2R at higher doses. Among CD4+ lymphocytes, at both doses, cefuroxime increased %Th1 population, with a parallel decrease in %Th2, %Th17, IL-17A, FOX-P3, and T-bet. Among the Th1 sub-population, changes were seen at higher cefuroxime doses, including increased viability and PD-1, and a decrease in FAS, IFN-γ and CD28, and IL-7R expression. Conclusions: The choice of antibiotics directly impacts immune function following major surgery, with cefuroxime associated with ex vivo immunomodulatory effects on CD4+ lymphocytes. The functional implications on the development of subsequent post-operative infectious complications and long-term cancer-free survival require further investigation.

## Linked entities

- **Proteins:** IFNG (interferon gamma), IL2 (interleukin 2), IL2RA (interleukin 2 receptor subunit alpha), IL17A (interleukin 17A), FOXP3 (forkhead box P3), TBX21 (T-box transcription factor 21), PDCD1 (programmed cell death 1), FAS (Fas cell surface death receptor), CD28 (CD28 molecule), IL7R (interleukin 7 receptor)
- **Chemicals:** amoxicillin (PubChem CID 33613), cefuroxime (PubChem CID 5479529), metronidazole (PubChem CID 4173)

## Full-text entities

- **Genes:** CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, SPATA2 (spermatogenesis associated 2) [NCBI Gene 9825] {aka PD1, PPP1R145, tamo}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, TBX21 (T-box transcription factor 21) [NCBI Gene 30009] {aka IMD88, T-PET, T-bet, TBET, TBLYM}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}
- **Diseases:** cancer (MESH:D009369), infectious complications (MESH:D003141), infection (MESH:D007239)
- **Chemicals:** cefuroxime (MESH:D002444), metronidazole (MESH:D008795), amoxicillin (MESH:D000658)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12561684/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12561684/full.md

## References

61 references — full list in the complete paper: https://tomesphere.com/paper/PMC12561684/full.md

---
Source: https://tomesphere.com/paper/PMC12561684